Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for rare neuromuscular and cardiomyopathy diseases. Its pipeline is centered on small-molecule drug candidates such as sevasemten and EDG-7500, which are being advanced through Phase 2 trials and preclinical development.

19.85

19.85

— Edgewise Therapeutics, Inc.
%
Sevasemten program55% Clinical-stage small-molecule therapy for rare neuromuscular diseases, including Becker and other muscular dystrophies.
EDG-7500 program25% Clinical-stage candidate being developed for hypertrophic cardiomyopathy.
Discovery pipeline10% Earlier-stage cardiometabolic programs, including EDG-003 and additional candidates.
Drug discovery platform10% Internal platform used to identify and optimize small-molecule precision medicines.

Edgewise does not yet sell approved products; its current 'customers' are clinical trial participants, investigators,...

  • Rare neuromuscular disease patientsprimary

    Patients with Becker, Duchenne and related muscular dystrophies who would use sevasemten if approved.

  • Hypertrophic cardiomyopathy patientsprimary

    Patients with HCM targeted by EDG-7500 clinical development and eventual commercialization.

  • Clinical trial ecosystemsecondary

    Investigators, CROs and sites that execute the company's Phase 2 studies and generate development data.

  • CDMO and manufacturing partnerssecondary

    Third-party manufacturers that supply active ingredient and fill-finish services for preclinical and clinical material.

  • Future payors and specialty prescribersemerging

    Government and commercial payors, plus specialists, that would determine access and uptake after approval.

Edgewise is headquartered in Boulder, Colorado and currently conducts development primarily in the United States...

  • •Headquartered in Boulder, Colorado, United States
  • •Clinical development is primarily U.S.-based today
  • •Plans to commercialize in the U.S. and select international markets
  • •International reimbursement systems may constrain pricing and access
  • •Manufacturing is outsourced to CDMOs rather than owned plants

Edgewise is prioritizing advancement of sevasemten and EDG-7500 through Phase 2 development while building the data...

01
Complete and read out Phase 2 sevasemten studiesshort-term

Clinical data in Becker and other muscular dystrophies is central to regulatory and partnering value.

02
Advance EDG-7500 in HCMshort-term

Diversifies the pipeline into cardiology and broadens the company's future commercial opportunity.

03
Prepare for commercialization and reimbursementmedium-term

Rare-disease drugs depend on payer coverage and pricing discipline to be commercially viable.

04
Expand discovery and manufacturing resiliencemedium-term

Additional candidates and redundant supply reduce single-asset and single-source risk.

Edgewise is a pre-revenue clinical-stage company, so its value depends heavily on successful trial outcomes, regulatory...

critical

Clinical development failure

Sevasemten and EDG-7500 are still in Phase 2, and efficacy or safety issues could halt programs.

Scope
Multiple ongoing Phase 2 trials in rare diseases
Materiality
high
high

Regulatory approval uncertainty

FDA and ex-U.S. regulators may require additional data or reject applications for rare-disease indications.

Scope
Becker, Duchenne, LGMD and HCM programs
Materiality
high
high

Reimbursement and pricing risk

Small patient populations require high per-patient pricing, but payors may restrict coverage or reimbursement levels.

Scope
U.S. and international commercialization
Materiality
high
high

Third-party manufacturing dependence

The company uses CDMOs on purchase-order terms and lacks redundant supply arrangements today.

Scope
API and fill-finish for sevasemten, EDG-7500 and EDG-15400
Materiality
medium
high

Capital needs and dilution

As a pre-revenue biotech, continued R&D and trial expansion may require additional financing.

Scope
Ongoing clinical and preclinical programs
Materiality
high
Accrued research and development expenses
Can shift expenses between periods and affect operating loss comparability
Clinical trial and manufacturing accruals
Quarterly R&D expense volatility
Stock-based compensation
Raises operating expenses without immediate cash outflow
Liquidity and going-concern assessment
Affects investor view of dilution and funding risk

PepGen Inc.

PEPG · Pharmaceutical Preparations

Vistagen Therapeutics, Inc.

VTGN · Pharmaceutical Preparations

Solid Biosciences Inc.

SLDB · Biological Products, (No Diagnostic Substances)

enGene Therapeutics Inc.

ENGN · Biological Products, (No Diagnostic Substances)

Odyssey Health, Inc.

ODYY · Surgical & Medical Instruments & Apparatus

Lexeo Therapeutics, Inc.

LXEO · Biological Products, (No Diagnostic Substances)

: 28/04/2026